Trial
NCT04234113
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
SOTIO Biotech AG
Collaborators
SOTIO Biotech a.s.
Condition
Thyroid Cancer
Intervention
Nanrilkefusp alfa
Why stopped
Due to lack of efficacy shown at the time of the interim analysis.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-27